Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50,232,186
-
Number of holders
-
84
-
Total 13F shares, excl. options
-
23,950,478
-
Shares change
-
-1,023,340
-
Total reported value, excl. options
-
$353,046,504
-
Value change
-
-$11,733,222
-
Put/Call ratio
-
0%
-
Number of buys
-
38
-
Number of sells
-
-46
-
Price
-
$14.74
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q1 2022
107 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q1 2022.
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) has 84 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23,950,478 shares
of 50,232,186 outstanding shares and own 48% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (1,930,322 shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1,746,300 shares), Deep Track Capital, LP (1,729,757 shares), Frazier Life Sciences Management, L.P. (1,572,192 shares), BlackRock Inc. (1,544,027 shares), Vivo Capital, LLC (1,533,559 shares), WELLINGTON MANAGEMENT GROUP LLP (1,346,742 shares), FRANKLIN RESOURCES INC (1,239,711 shares), VANGUARD GROUP INC (1,166,652 shares), and STATE STREET CORP (938,867 shares).
This table shows the top 84 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.